Genmab A/S (GNMSF) Projected to Announce Earnings on Thursday

Genmab A/S (OTCMKTS:GNMSF) will likely be issuing its results after the market closes on Thursday, August 6th. Analysts expect Genmab A/S to post earnings of $3.53 per share and revenue of $1.1110 billion for the quarter.

Genmab A/S Stock Performance

Shares of GNMSF stock opened at $289.16 on Thursday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18. The firm has a market capitalization of $17.80 billion, a price-to-earnings ratio of 21.81 and a beta of 0.78. Genmab A/S has a one year low of $216.31 and a one year high of $352.00. The company has a 50 day moving average price of $264.67 and a 200 day moving average price of $281.35.

About Genmab A/S

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.